← Oncology Approval Tracker

FDA DECISION ·

Rybrevant + carboplatin + pemetrexed

amivantamab-vmjw with carboplatin and pemetrexed · Janssen Biotech

FDA approvalNew or expanded indicationNon-small cell lung cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

First-line treatment of locally advanced or metastatic non-small cell lung cancer with an FDA test-confirmed EGFR exon 20 insertion, using amivantamab with carboplatin and pemetrexed.

LAMPGEN ANALYSIS

Why it matters

The PAPILLON-based approval brought the antibody into first-line treatment for EGFR exon 20 insertion disease.

What research teams should watch

Make exon 20 insertion testing explicit and prepare for the initial infusion schedule and reaction monitoring.

PRIMARY RECORDS

Sources